Effect of metabolic syndrome and its components on survival in colorectal cancer: a prospective study

Ali Ahmadi¹, Mehdi Noroozi², Mohamad Amin Pourhoseingholi³, Seyyed-Saeed Hashemi-Nazari⁴*

¹Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran
²Department of Epidemiology, School of Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
³Gastroenterology and Liver Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
⁴Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Seyyed-Saeed Hashemi-Nazari, Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: saeedb1999@yahoo.com

Introduction: Metabolic syndrome (MetS) may increase the risk of colorectal cancer (CRC). This study was aimed to design a model and to examine the prognostic effect of MetS on survival time in the patients with CRC.

Objectives: This study was aimed to design a model and to examine the prognostic effect of MetS on survival time in the patients with CRC.

Patients and Methods: Data were collected from 1127 cases of CRC from Cancer Registry Center of the Research Institute of Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran. In this cohort study, patients were divided into two groups based on the presence of MetS. We tested the prognostic value of MetS in the patients by Cox proportional hazard modeling.

Results: Mean ± standard deviation of the patients’ age at diagnosis in MetS group and non-MetS group was 56 ± 13 years old and 53 ± 15 years old respectively. Tumor stage as an independent variable affected CRC survival. The mean survival time of the MetS and non-MetS groups was 23 and 27 months respectively. Independent variables like tumor stage (hazard ratio [HR], 1.76; 95% CI, 0.29–0.90) and educational level (HR, 0.50; 95% CI, 0.23–0.97) had significant effect on CRC survival and MetS (HR, 0.95; 95% CI, 0.52–1.5), tumor size (HR, 1.390; 95% CI, 1.237–1.560), family history, age, gender, and smoking had non-significant effect on CRC survival.

Conclusion: MetS could be a prognostic factor for survival in the patients with CRC. The results suggested that effect of MetS was not significant.

Implication for health policy/practice/research/medical education: Although metabolic syndrome (MetS) has been investigated as a potential risk factor for colorectal cancer (CRC) and could be a prognostic factor for survival in the patients with CRC, but its effect was not significant and hence the way could be paved for decision makers and planners in health system.

Please cite this paper as: Ahmadi A, Noroozi M, Pourhoseingholi MA, Hashemi-Nazari SS. Effect of metabolic syndrome and its components on survival in colorectal cancer: a prospective study. J Renal Inj Prev. 2015; 4(1): 15-19. DOI: 10.12861/jrip.2015.05
CRC are diagnosed and 500,000 deaths occur due to its worldwide. In the United States CRC is the third leading cancer in both genders and the third cancer resulting in death, comprising 9% of the whole mortalities from cancers (6). According to the cancer registry, CRC incidence in five continents varies from 3% in Africa up to 40% in the United States. In Europe, CRC incidence varies from 12.1% in Belarus to 30.5% in Italy (7,8). In addition, CRC was the most frequently diagnosed cancer and the second common cause of the death from cancers and comprised 13% of all new cancer cases in both genders in organization for economic cooperation and development member countries in 2008. MetS, alongside cardiovascular risks, has been offered in some epidemiological studies as being associated with several cancers including CRC. There is an overlap among risk factors for MetS, diabetes mellitus, and CRC (9,10).

In Iran according to the national cancer registry's report in 2009, acoustic startle response (ASR) of CRC in women was 10.89 (ranked as the third) and in men was 11.31 (ranked as the fifth). In a study carried out by Ansari et al. in 2005, in the provinces of Ardabil, Gilan, Mazandaran, Golestan, and Kerman, ASR of CRC was 8.2 in men and 7 in women, which is approximate to the national cancer registry's report (11-13). Although MetS has been investigated as a potential risk factor for CRC (13), various studies have obtained conflicting results relevant to MetS-associated CRC risk of death. However, a study in China showed that MetS had no obvious effect on observable survival and recurrence free rate (9,14,15). Several meta-analysis have been conducted about association between MetS and CRC and reported heterogeneity and homogeneity (2,5,16,17). To the best of our knowledge, no study of CRC survival and MetS to date has been conducted in Iran (18-20).

Objectives
The aim of this study is to examine whether the MetS is associated with survival of the patients with CRC.

Patients and Methods
The present study is a prospective, cohort one. Data were obtained from cancer registry center of the research institute of gastroenterology and liver disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The patients from public and private collaborative hospitals were treated and referred to the cancer registry. This study is based on the data of cancer registry including demographic factors (sex, age, education, job, etc.), medical records, family history, and diagnosis information (symptoms at diagnosis, tumor metastasis, grade of tumor, etc.). All patients with CRC diagnosis by the pathology report of cancer registry were considered as eligible. Finally, 1219 patients (802 [66%] with colon cancer, 392 [32%] with rectal cancer, and 25 [2%] with unknown cause) were enrolled. The follow-up duration was determined from the date of diagnosis up to first of October 2008 as the time of the death from the disease (as the exact failure time) or survival (as the censoring time). First of January 2002 was considered as the start time of the study. Deaths were confirmed through calling relatives of the patients by telephone. On few (2%) CRC patients, no clear information was obtained about the cause of death except the date of death; therefore, their data were excluded from the analysis. There were 1127 patients (including 690 men and 437 women) with complete follow-up data. These patients were divided into two groups based on the presence of MetS. A physician interviewed the participants separately, performed a physical examination, and obtained a detailed medical history. The data were recorded carefully. Body weight (kg) and height (m) were measured to compute body mass index (BMI). Blood pressure was measured using the right arm and a standard mercury sphygmomanometer in sitting position after a 5-minute rest, and the mean systolic and diastolic blood pressure values of the two measurements were recorded. After measurement of blood pressure, while the participant was fasting, a venous blood sample was taken for determination of the serum glucose. For all patients and based on medical file, the data on age, sex, smoking, size of the tumor, histological type, degree of differentiation (low degree as the referent) or tumor, node, metastasis (TNM) stage, and alcohol drinking history, separately or in combination, were used in the analysis.

Ethical issues
(1) The research followed the tenets of the Declaration of Helsinki; (2) informed consent was obtained; (3) the research was approved by ethical committee of Shahid Beheshti University of Medical Sciences. This study with approval No. 686 issued by Shahid Beheshti University of Medical Sciences Ethics Committee was conducted after obtaining the informed consent from the patients.

Statistical analysis
Continuous variables in this study were expressed as mean ± standard deviation (SD). The variables that were statistically significant by univariate analysis were included in a multivariate analysis, confirmed by Cox regression (Cox proportional hazards model) with forward stepwise selection of covariates and with enter and remove limits of P values of less than 0.050 and greater than 0.100, respectively. Cox proportional hazards model was determined as primary mode of analysis, through which adjustment for age, smoking, and alcohol drinking and other variables was performed. The assumption of proportionality of the hazards was tested and found as being not violated. In the final model, P values of less than 0.05 were considered statistically significant. Stata 12 software was used for the statistical analysis.

Results
The mean (± SD) follow-up time for the patients with CRC was 26 (± 25) months. The mean (± SD) age at diagnosis was 54 (± 14) years in CRC patients. Mean (± SD) age
at diagnosis was 56 (± 13) years in MetS group and was 53 (± 15) years in non-MetS. There were non-significant differences in the age at diagnosis between the two groups (P > 0.060). In the MetS group, 187 tumors were highly differentiated, 52 were moderately differentiated, and 13 were slightly differentiated. In the non-MetS group, 273 tumors were highly differentiated, 177 were moderately differentiated, and 46 were slightly differentiated; no significant difference in degree of differentiation was observed between the two groups (Chi-square, 0.502; P = 0.778). Mean (± SD) size of tumor was 76 (± 9) and 75 (± 13) mm3 in MetS and non-MetS groups, respectively. The mean survival time in the MetS and non-MetS groups was 23 and 27 months respectively. Survival time was shorter in the MetS compared to the non-MetS group. Survival curve revealed that survival of the MetS group was worse than the non-MetS group. Variables examined by univariate analysis for overall survival of CRC included sex, age, smoking, size of the tumor, histological type, degree of differentiation (low degree as the referent) or TNM stage, with MetS (or non-MetS group as the referent), family history, education level, alcohol drinking history, and marital status. Then variables obtained statistically significant by univariate analysis (P < 0.05) were included in a multivariate analysis. Independent variables like tumor stage (hazard ratio [HR], 1.76; 95% CI, 0.29–0.90) and educational level (HR, 0.50; 95% CI, 0.23–0.97) had significant effect on CRC survival and MetS (HR, 0.95; 95% CI, 0.52–1.5), tumor size (HR, 1.390; 95% CI, 1.237–1.560), family history, age, gender, and smoking had non-significant effect on CRC survival (Table 1).

**Discussion**

Cancer is the second leading cause of death in the world and is the third leading cause of mortality in Iran. Regarding this purpose, we conducted this study on 1227 Iranian CRC patients to evaluate the effect of MetS on survival of CRC. The incidence of MetS is increasing due to urbanization, aging, diet structure, and lifestyle (21-24). Recent studies show a relationship between diet structure and the prevalence of CRC (25, 26). However, the studies about the association between CRC prognosis and MetS have been less conducted. Marrero et al. reported a moderate association of post load plasma glucose and insulin resistance syndrome with CRC and found that the survival rate of breast cancer in the MetS group was higher than that of the control group; however, there are few reports on the association between MetS and CRC. In our study, no obvious differences were observed in tumor differentiation between the two groups. Moreover, our study showed that the mean survival time of the MetS group was shorter than that of the non-MetS group, with a statistically non-significant difference. However, results of some other studies showed the mean survival time of the MetS group was shorter than that of the non-MetS group, with a statistically significant difference (16). This difference might be due to the definition of MetS or mode of survival estimation (i.e. diagnosis to death or treatment to death). Shen et al. found that MetS and survival of colon cancer were related but MetS had no effect on rectal cancer (10). Also, Colangelo et al. reported no association between MetS and prognosis of CRC (27, 28). The difference in the findings could be due to different definitions of MetS and/or the method of survival estimation (from the diagnosis till death or from treatment till death). Furthermore, in our multivariate analysis of survival, we found that worse TNM stage and size of the tumor were important independent risk factors for survival in CRC, which is

| Characteristics | Hazard Ratio | P value | 95% CI |
|-----------------|-------------|---------|--------|
|                 | Crude       | Adjusted| Univariate | Multivariate | Univariate | Multivariate |
| MetS            |             |         |         |         |         |         |
| Yes             | 0.81        | 0.95    | 0.05    | 0.6     | 0.06-3.78 | 0.52-1.22 |
| No              | 1           | 1       |         |         |         |         |
| SEX             |             |         |         |         |         |         |
| Male            | 0.86        | 1.09    | 0.3     | 0.7     | 0.66-1.4 | 0.67-1.77 |
| Female          | 1           | 1       |         |         |         |         |
| Marital status  |             |         |         |         |         |         |
| Married         | 1           | 1       | -       | -       | -       | 0.88-3.49 |
| Single          | 1.92        | 1.75    | 0.004   | 0.1     | 1.23-3.0 |         |
| Education       |             |         |         |         |         |         |
| Illiterate      | 1           | 1       | 1       |         |         |         |
| Primary school  | 0.68        | 0.5     | 0.05    | 0.03    | 0.465-1.0 | 0.26-94  |
| High school     | 0.68        | 0.4     | 0.07    | 0.02    | 0.45-1.05 | 0.20-0.89 |
| university      | 0.67        | 0.6     | 0.08    | 0.12    | 0.43-1.04 | 0.36-1.2  |
| Tumor grade     |             |         |         |         |         |         |
| grade II        | 1.46        | 1.2     | 0.03    | 0.4     | 1.03-2.08 | 0.73-1.9  |
| III to IV       | 1.89        | 2.2     | 0.01    | 0.01    | 1.14-3.33 | 1.9-4.4   |
| Age at diagnosis| 1.03        | 1.00    | 0.3     | 0.9     | 0.9-1.03  | 0.98-1.01 |
| Hypertension    | 0.82        | 0.83    | 0.4     | 0.6     | 0.5-1.64  | 0.42-1.64 |
| Diabetes        | 0.9         | 1.45    | 0.7     | 0.3     | 0.5-1.64  | 0.71-2.95 |
| High body mass index | 0.71  | 0.62    | 0.001   | 0.006   | 0.35-6.8  | 0.44-8.7  |
Ahmadi A et al.

consistent with others’ findings.

Limitations
There were some limitations in our study. The information gathered about opioid and drug abuse history and smoking was incomplete, based on only two categories of “never” and “current or past user”, and qualitative; quantitative data about these two factors could yield more exact results. There was no data of dietary habits of the patients, as well.

Conclusion
Our study showed that the mean survival time of the MetS group was shorter than that of the non-MetS group, with a statistically non-significant difference. MetS could be a prognostic factor for survival in the patients with CRC. The results suggested that effect of MetS was not significant.

Acknowledgments
Hereby we greatly appreciate the valuable contribution of Shahid Beheshti University of Medical Sciences and Cancer Registry Center of Research Institute of Gastroenterology and Liver Disease to this study.

Authors’ contributions
All authors contributed to design of the research. AA, MN, MP and SHN conducted the research. AA and SHN analyzed the data. AA, MN and SHN prepared the manuscript. All authors read, revised, and approved the final manuscript.

Conflict of interests
The authors declare no conflict of interests.

Ethical considerations
Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission, redundancy) have been completely observed by the authors.

Funding/Support
This study with approval No. 686 issued by Shahid Beheshti University of Medical Sciences. Data collection for this research was supported by the Cancer Registry Database of the Research Center for Gastroenterology and Liver Diseases affiliated to Shahid Beheshti University of Medical Sciences. The funding sources played no role in the study design, data analysis, and manuscript writing, or in the decision to submit this manuscript for publication.

References
1. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007; 86(3): s836-42.
2. Jinjuvadia R, Lohia P, Jinjuvadia C, Montoya S, Liangpunsakul S. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol 2013;47(1):33-44.
3. Ahmadi A, Hasanazadeh J. To Determine the Relative Factors on Hypertension in Kohrang, Chaharmahal & Bakhtiari Province. Iranian Journal of Epidemiology 2008; 4(2): 19-25.
4. Ahmadi A, Hasanazadeh J. Metabolic Control And Care Assessment in Patients with Type 2 Diabetes In Chaharmahal & Bakhtiari Province 2008. Iranian Journal of Endocrinology & Metabolism 2009;11(1):33-39.
5. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013; 44(3): 634-47.
6. Kono S, Handa K, Hayabuchi H, Kiyohara C, Inoue H, Marugame T, et al. Obesity, weight gain and risk of colon adenomas in Japanese men. J Cancer Res 1999; 90(8): 805-11.
7. Morrison DS, Parr CL, Lam TH, Ueshima H, Kim HC, Jee SH, et al. Behavioural and metabolic risk factors for mortality from colon and rectum cancer: analysis of data from the Asia-Pacific Cohort Studies Collaboration. Asian Pac J Cancer Prev 2013; 14(2): 1083-7.
8. Ahmadi A, M Mobasheri, Hashemi-Nazari SS. Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal cancer and their median survival time: A cohort study. Journal of Research in Medical Sciences 2014; 19(9): 840-45.
9. Yang Y, Mauldin PD, Ebeling M, Hulsey TC, Liu B, Thomas MB, et al. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer 2013; 119(8): 1512-20.
10. Shen Z, Ye Y, Bin L, Yin M, Yang X, Jiang K, et al. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. Am J Surg 2010; 200(1):59-63.
11. Ahmadi A, Hashemi-Nazari SS, Molavi-Chooobini Z, Nasri H. Patten Comparison of Hypertension and Type2 Diabetes Mellitus in Patients with Colorectal Cancer. J Isfahan Med Sch 2014; 32(302).
12. Ahmadi A, Hashemi Nazari S, Mobasher M. Does ethnicity affect survival following colorectal cancer? A prospective, cohort study using Iranian cancer registry. MJIRI 2014; 28(2): 83-8.
13. Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO, et al. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev 2007; 16(8): 1543-6.
14. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 2008; 15(9): 2388-94.
15. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J
Metabolic syndrome and colorectal cancer

Gastroenterol. 2011; 106(11): 1911-21.

16. Wang XS, Armstrong ME, Cairns BJ, Key TJ, Travis RC. Shift work and chronic disease: the epidemiological evidence. Occup Med (Lond) 2011; 61(2): 78-89.

17. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012; 35(11): 2402-11.

18. Forootan M, Tabatabaefar M, Yahyaei M, Maghsoudi N. Metabolic syndrome and colorectal cancer: a cross-sectional survey. Asian Pac J Cancer Prev 2012; 13(10): 4999-5002.

19. Moradi A, Khayamzadeh M, Guya M, Mirzaei HR, Salmanian R, Rakhsha A, et al. Survival of colorectal cancer in Iran. Asian Pac J Cancer Prev 2009; 10(4): 583-6.

20. Moghimi-Dehkordi B, Safaee A, Pourhoseingholi MA, Zali MR. Effect of demographic and clinicopathologic factors on prognosis of early gastric cancer in Iran. Asian Pac J Cancer Prev 2008; 9(4): 585-8.

21. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol 2010; 25(6): 375-84.

22. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012; 49(1): 89-96.

23. Savva SC, Lamnisos D, Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI: A meta-analysis. Diabetes Metab Syndr Obes 2013; 6: 403-19.

24. Yamada T, Harai K, Kadowaki T. Chewing betel quid and the risk of metabolic disease, cardiovascular disease, and all-cause mortality: a meta-analysis. Plos One 2013; 8(8): e70679.

25. Kirkegaard H, Johnsen NF, Christensen J, Frederiksen K, Overvad K, Tjonneland A. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ 2010; 341: c5504.

26. Kocic B, Katic D, Brankovic S. Dietary flavonoid intake and colorectal cancer risk: evidence from human population studies. J BUON 2013; 18(1): 34-43.

27. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11(4): 385-91.

28. Lloyd-Jones DM, Liu K, Colangelo LA, Yan LL, Klein L, Loria CM, et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation 2007; 115(8): 1004-11.

Copyright © 2015 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.